Reading time is 1 mins
.
.
IN NEW STUDY: THE RESULTS ARE BETTER WHEN ACUTE HEART FAILURE IS TREATED WITH TYPE 2 DIABETES MEDICATION!
When treated with empagliflozin, a decrease in all-cause deaths was observed in adults hospitalized for acute heart failure.
.
THE STUDY FIND
According to recent studies, empagliflozi adults during hospitalization due to Acute Heart Failure Treated with higher survival, lower heart failure Hospital re-admission and the risk of a clinical benefit, such as a general improvement in quality of life seen today in the American Heart Association’s Scientific Sessions in 2021, is presented.
Empagliflozin is a drug that was originally used to treat patients with type 2 diabetes, and recently has become an important treatment in patients with chronic heart failure.
“Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: The Main Results of the study” set out to determine whether this drug, an SGLT2 inhibitor, will help adults hospitalized for acute heart failure after their condition stabilizes.
.
THE STUDY RESULTS
Adults treated with empagliflozin were 36 percent more likely to see a clinical benefit, such as a decrease in all-cause mortality, fewer heart failure events, and improvement in heart failure symptoms, compared to those who received a placebo.
The benefits include a decrease in all-cause mortality (8.3% in placebo areas versus 4.2% in adults treated with empagliflozin), a decrease in heart failure events (10.6% in participants taking empagliflozin and 14.7% for those taking placebo).
- Participants experienced improvements in all-cause deaths, heart failure events, or heart failure symptoms, regardless of the type of heart failure or whether they had type 2 diabetes.
.
- Participants taking empagliflozin experienced fewer serious heart failure events compared to those taking placebo (32.3% vs. 43.6%, respectively).
.
.
.
.
Turkey's world-renowned organ transplant specialist. Dr. Demirbaş has 104 international publications and 102 national publications.
Physician's Resume:
Born on August 7, 1963 in Çorum, Prof. Dr. Alper Demirbaş has been continuing his work as the President of MedicalPark Antalya Hospital Organ Transplantation Center since 2008.
Prof. who performed the first tissue incompatible kidney transplant in Turkey, the first blood type incompatible kidney transplant, the first kidney-pancreas transplant program and the first cadaveric donor and live donor liver transplant in Antalya. Dr. As of August 2016, Alper Demirbaş has performed 4900 kidney transplants, 500 liver transplants and 95 pancreas transplants.
In addition to being the chairman of 6 national congresses, he has also been an invited speaker at 12 international and 65 national scientific congresses. Dr. Alper Demirbaş was married and the father of 1 girl and 1 boy.
Awards:
Eczacibasi Medical Award of 2002, Akdeniz University Service Award of 2005, Izder Medical Man of the Year Award of 2006, BÖHAK Medical Man of the Year Award of 2007, Sabah Mediterranean Newspaper Scientist of the Year Award of 2007, ANTIKAD Scientist of the Year Award of 2009, Social Ethics Association Award of 2010, Işık University Medical Man of the Year Award of 2015, VTV Antalya's Brand Value Award of 2015.
Certificates:
Doctor of Medicine Degree Hacettepe University Faculty of Medicine Ankara, General Surgeon Ministry of Health Turkey EKFMG (0-477-343-8), University of Miami School of Medicine Member of Multiple Organ Transplant, ASTS Multiorgan Transplant Scholarship. Lecturer at Kyoto University. Lecturer at University of Essen, Research assistant at the University of Cambridge .
Professional Members:
American Society of Transplant Surgeons, American Transplantation Society Nominated, Middle East and Southern Africa Council Transplantation Society 2007, International Liver Transplantation Association, Turkish Transplantation Association, Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association.
Disclaimer:
Our website contents consist of articles approved by our Web and Medical Editorial Board with the contributions of our physicians. Our contents are prepared only for informational purposes for public benefit. Be sure to consult your doctor for diagnosis and treatment.